FDA Approves Ruxolitinib (Opzelura) for Vitiligo

This new topical JAK inhibitor cream is the first medication that can restore skin pigment in people with the autoimmune disease vitiligo.

Related Keywords

New York ,United States ,Daniel Gutierrez ,Langone Health ,Grossman School Of Medicine ,Vitiligo Research Foundation ,National Institute Of Arthritis ,Drug Administration ,New York City ,National Institute ,Vitiligo Area Scoring Index ,Comes With ,Black Box ,Can Use Ruxolitinib ,Means Better Access ,Vitiligo Research ,